Keros Therapeutics Inc stock is traded at $9.45, with a volume of 238,430. It is down -12.74% in the last 24 hours and down -14.17% over the past month. Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Previous Close:
$10.83
Open:
$10.84
24h Volume:
238,430
Relative Volume:
1.59
Market Cap:
$187.37M
Revenue:
$33.18M
Net Income/Loss:
-$85.15M
P/E Ratio:
-
EPS:
-$3.01
Net Cash Flow:
-$58.25M
1W Performance:
-14.40%
1M Performance:
-14.17%
6M Performance:
-19.78%
1Y Performance:
-41.56%
1-Day Range:
$0.00$0.00
1-Week Range:
$9.37$11.39
52-Week Range:
$9.37$22.55
Keros Therapeutics Inc Stock (KROS) Company Profile
Name
Keros Therapeutics IncSector
HealthcareIndustry
BiotechnologyPhone
617-314-6297Address
1050 WALTHAM STREET, SUITE 302, LEXINGTON, MA, USAMarket Cap
Revenue
Net Income
Cash Flow
EPS